Metagenomi Therapeutics Inc Revenue Growth Rates (MGX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Metagenomi Therapeutics Inc   (NASDAQ: MGX)
 

MGX's Revenue Growth by Quarter and Year

Metagenomi Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MGX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -0.26
1st Quarter March 1.25
FY 0.99





MGX Revenue second quarter 2026 Y/Y Growth Comment
Metagenomi Therapeutics Inc in the second quarter 2026 recorded of $ -0.26 millions.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 47 other companies have achieved higher Revenue growth. While Metagenomi Therapeutics Inc ' s Revenue meltdown of -103.02% ranks overall at the positon no. 3426 in the second quarter 2026.


MGX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -59.31 % -22.5 % -
3rd Quarter September - -24.76 % -6.88 % -
2nd Quarter June - -57.47 % 76.46 % -
1st Quarter March -69.73 % -62.99 % 28.87 % -
FY   - -51.79 % 16.82 % -

Financial Statements
Metagenomi Therapeutics Inc 's second quarter 2026 Revenue $ -0.26 millions MGX's Income Statement
Metagenomi Therapeutics Inc 's second quarter 2025 Revenue $ 8.51 millions Quarterly MGX's Income Statement


MGX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -54.85 % -16.51 % 0.32 %
3rd Quarter September - 1.76 % -42.48 % 8.99 %
2nd Quarter June - 106.05 % 79.3 % 30.95 %
1st Quarter March -68.03 % -57.02 % -10 % -
FY (Year on Year)   - -51.79 % 16.82 % -


Back to MGX Growth rate Comparisons >> Back to MGX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #48
Healthcare Sector #467
Overall #3426

Revenue Y/Y Growth Statistics
High Average Low
16.84 % -33.31 % -59.84 %
(Dec 31 2024)   (Jun 30 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #48
Healthcare Sector #467
Overall #3426
Revenue Y/Y Growth Statistics
High Average Low
16.84 % -33.31 % -59.84 %
(Dec 31 2024)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Metagenomi Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MGX's II. Quarter Q/Q Revenue Comment
Recent accomplishment of -0.26 millions by Metagenomi Therapeutics Inc come out even worse considering the 1.25 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Metagenomi Therapeutics Inc achieved highest sequential Revenue growth. While Metagenomi Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is .


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MGX's II. Quarter Q/Q Revenue Comment
Recent accomplishment of -0.26 millions by Metagenomi Therapeutics Inc come out even worse considering the 1.25 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Metagenomi Therapeutics Inc achieved highest sequential Revenue growth. While Metagenomi Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is .


Metagenomi Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 13.56 $ 22.33 $ 25.21 $ 30.91 $ 33.77
Y / Y Revenue Growth (TTM) -59.84 % -50.66 % -51.79 % -43.88 % -39.62 %
Year on Year Revenue Growth Overall Ranking # 3531 # 2970 # 2805 # 0 # 0
Seqeuential Revenue Change (TTM) -39.27 % -11.42 % -18.45 % -8.45 % -25.4 %
Seq. Revenue Growth (TTM) Overall Ranking # 3426 # 2686 # 2564 # 2306 # 0


Cumulative Revenue growth Comment
Metagenomi Therapeutics Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -59.84% year on year, at Jun 30 2026 compare to the -50.66% decrease at Mar 31 2026. If the Metagenomi Therapeutics Inc 's fiscal year would end at Jun 30 2026, annual Revenue would be $14 millions.

In the Healthcare sector 485 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2970 to 3531.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 48
Healthcare Sector # 486
Overall # 3531

Revenue TTM Y/Y Growth Statistics
High Average Low
16.84 %
 -33.31 %
-59.84 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 48
Sector # 467
S&P 500 # 3426
Cumulative Revenue growth Comment
Metagenomi Therapeutics Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -59.84% year on year, at Jun 30 2026 compare to the -50.66% decrease at Mar 31 2026. If the Metagenomi Therapeutics Inc 's fiscal year would end at Jun 30 2026, annual Revenue would be $14 millions.

In the Healthcare sector 485 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2970 to 3531.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 48
Healthcare Sector # 486
Overall # 3531

Revenue TTM Y/Y Growth Statistics
High Average Low
16.84 %
-33.31 %
-59.84 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 48
Sector # 467
S&P 500 # 3426




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MGX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Metagenomi Therapeutics Inc Revenue Growth Rates (MGX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Metagenomi Therapeutics Inc (CIK 1785279).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-342400
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Metagenomi Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.